Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06301191
Other study ID # 133/21-02-2022
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2022
Est. completion date May 1, 2024

Study information

Verified date March 2024
Source Attikon Hospital
Contact VAIA LAMBADIARI, Professor
Phone 2105831148
Email vlambad@otenet.gr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.


Description:

The cardiovascular benefits of semaglutide are established; however, its effect on surrogate vascular markers and liver function is not known.The aim of our study is to investigate the effects of semaglutide on vascular,endothelial and liver function in patients with type 2 diabetes and non-alcoholic fatty liver disease. A.Overall, 50 patients with diabetes mellitus type 2 and NAFLD will be studied at baseline ,at four and twelve months of treatment: 25 patients will be treated with semaglutide 25 patients will be treated with D-PP4 inhibitors. B. In all patients, the investigators will measure the pulse wave velocity (measured in m/s), pulse wave augmentation index [which is calculated by the formula (P2-P1)/PP x 100, where P1 stands for peak systolic pressure, P2 stands for second peak systolic pressure due to wave reflection and PP stands for Pulse Pressure ], central systolic blood pressure (SBPao, measured in mm Hg) and central pulse pressure (PPao, measured ) with Arteriograph, Mobilograph and Complior, and perfused boundary region of sublingual vessels (5-25 μm in size) using a high-resolution camera with Sideview Darkfield Imaging technique (Microscan, Glucockeck). Perfused boundary region consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx. Increased Perfused boundary region is considered to be an accurate indicator of the reduction of endothelial glycocalyx thickness due to plasma penetration into the glycocalyx.Liver steatosis and stiffness will be measured using Fibroscan® Mini+ 430 (Echosens, Paris, Île-de-France). Controlled Attenuation Parameter (CAP) score will be used as an index of liver fat content, with normal values being < 238 dB/m. E score will be used as an index of liver fibrosis, with normal values being 2- 6 kPa. The examination will be carried out at the Laboratory of Preventive Cardiology of the 2nd Department of Cardiology of the University of Athens at "Attikon" Hospital.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date May 1, 2024
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Diabetes Mellitus type 2 - NAFLD Exclusion Criteria: - malignancies - chronic inflammatory disease - chronic kidney disease (estimated glomerular filtration rate <60 ml/min/m2 for a period of at least 90 days) - peripheral vascular disease - retinopathy - previous therapy with a Glucagon-like peptide-1 agonist. - None of the female patients was on hormone replacement treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Semaglutide, 1.0 mg/mL
Semaglutide, 1.0 mg/mL
Dipeptidyl Peptidase 4 inhibitor
Dipeptidyl Peptidase 4 inhibitor

Locations

Country Name City State
Greece Attikon University General Hospital Athens

Sponsors (1)

Lead Sponsor Collaborator
Attikon Hospital

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of arterial stiffness markers difference among treatment groups Comparison of pulse wave velocity difference among treatment groups. Two non-invasive pressure sensors will be used to record the carotid and femoral waveforms and the distance between the two arterial sites will be measured with a tape measure. Pulse wave velocity is calculated as the distance divided by transit time between waves (m/s). 12 months
Primary Comparison of endothelial glycocalyx thickness difference among treatment groups The investigators will measure the perfused boundary region (PBR) of the sublingual arterial microvessels (ranged from 5 to 25 µm) using Sidestream Darkfield imaging that provides a direct, noninvasive, and fast method for the assessment of the endothelial glycocalyx. The PBR is the cell-poor layer which results from the phase separation between the flowing red blood cells (RBC) and plasma on the surface of the microvessel lumen. The PBR includes the most luminal part of glycocalyx that does allow cell penetration. Thus, an increased perfused boundary region is consistent with deeper penetration of erythrocytes into glycocalyx, indicating a loss of glycocalyx barrier properties and is a marker of reduced glycocalyx thickness. 12 months
Primary Comparison of liver stiffness difference among treatment groups CAP score will be used as an index of liver fat content, with normal values being < 238 dB/m. <237 dB/m (S0, no steatosis), 237 -259 dB/m (S1, mild steatosis), 259 -291 dB/m (S2, moderate steatosis), and 291 -400 dB/m (S3,severe steatosis). E score will be used as an index of liver fibrosis. The cut-off values for fibrosis (F) were as follows:(1) <5.5 kPa (F0, no fibrosis), (2) 5.5-8.0 kPa (F1, mild fibrosis), (3) 8.0-10.0 kPa (F2, moderate fibrosis),(4) 11.0-16.0 kPa (F3, severe fibrosis), and (5) >16.0 kPa (F4, cirrhosis). 12 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting NCT04954313 - Baseline Oral Health Study: UnCoVer the Connections to General Health Phase 4
Not yet recruiting NCT06437782 - Exploration of Health Literacy in Diabetes in Reunion Island and France
Completed NCT01354925 - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan Phase 4
Completed NCT01206725 - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction N/A
Completed NCT00997282 - A Study of OPC-262 in Patients With Type 2 Diabetes Phase 2/Phase 3
Completed NCT00637546 - Gait and Balance of Diabetes Type 2 Patients Phase 2/Phase 3
Completed NCT00464880 - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy Phase 1/Phase 2
Withdrawn NCT02057497 - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms N/A
Active, not recruiting NCT05014204 - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes N/A
Recruiting NCT03662217 - Personalized Nutrition for Diabetes Type 2 N/A
Completed NCT04276051 - Cryovagotomy Diabetes Trial N/A
Completed NCT02569684 - Effects of Prebiotics on GLP-1 in Type 2 Diabetes N/A
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Terminated NCT01722474 - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness. N/A
Completed NCT00977262 - Postprandial Inflammation and Fatty Acids N/A
Completed NCT00518427 - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine Phase 4
Recruiting NCT05378620 - Project Dulce for Filipino-Americans With Type 2 Diabetes N/A
Recruiting NCT03834207 - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy N/A
Active, not recruiting NCT05228067 - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity N/A